ClinicalBiostats

Clinical Trials

See the methods at work.

Statistical analyses of real clinical trials: design, endpoints, results and interpretation, organized by therapeutic area and linked to the methods behind them.

11,187 trials analyzed so far

Trials that use: ANCOVA

New to this method? Read the tutorial →

3,789 results

UHSIndependent statistical analysis of Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01632267).Phase NAResults postedn = 104NCT01632267
UKBCIndependent statistical analysis of The Use of a High-frequency Ultrasonic Knife in Breast Cancer Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 94NCT00996632
UNITSIndependent statistical analysis of The Urinary Incontinence Treatment Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03057834).Phase NAResults postedn = 70NCT03057834
UPLIFTIndependent statistical analysis of Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 132NCT05686408
UVA-Gen001Independent statistical analysis of Study of Genistein in Pediatric Oncology Patients (UVA-Gen001): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02624388).Phase 2Results postedn = 4NCT02624388
V-EXTRA-CVDIndependent statistical analysis of A Nurse-led Intervention to Extend the Veteran HIV Treatment Cascade for Cardiovascular Disease Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 305NCT04545489
VA-TECIndependent statistical analysis of Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01855399).Phase NAResults postedn = 290NCT01855399
VALUEIndependent statistical analysis of Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel…Phase NAResults postedn = 427NCT02750800
VATIndependent statistical analysis of Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 32NCT01750268
VC01-103Independent statistical analysis of A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1/2Results postedn = 31NCT04678557
VECTORIndependent statistical analysis of Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 636NCT01396421
VEGAIndependent statistical analysis of Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02396316).Phase 3Results postedn = 54NCT02396316
VENICE IIIndependent statistical analysis of A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer…Phase 3Results postedn = 210NCT02980731
VENTUREIndependent statistical analysis of the VENTURE phase 3 trial evaluating dupilumab in patients with severe steroid-dependent asthma, including its randomized design, oral corticosteroid reduction endpoints, ANCOVA, logistic regression, missing-data methods, and reported…Phase 3Results postedn = 210NCT02528214
VENUSIndependent statistical analysis of Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 722NCT01400776
VIBRANTIndependent statistical analysis of Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO): primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 183NCT01521559
VICARESIndependent statistical analysis of A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 19NCT03311269
VICTOSIndependent statistical analysis of Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 315NCT01673282
VIEW 2Complete statistical analysis of VIEW 2, the randomized phase 3 trial comparing aflibercept with ranibizumab in wet age-related macular degeneration, including non-inferiority methodology, ANCOVA, risk differences, and reported week 52 results.Phase 3Results postedn = 1,240NCT00637377
VIEW1A detailed statistical analysis of VIEW1, the randomized phase 3 trial evaluating aflibercept injection versus ranibizumab in patients with macular degeneration, including its non-inferiority design, primary visual-acuity endpoint, ANCOVA analyses, and reported…Phase 3Results postedn = 1,217NCT00509795
VisipaqueIndependent statistical analysis of Comparison of Contrast Agents During CT Angiography: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01534975).Phase NAResults postedn = 513NCT01534975
Vita-ShockIndependent statistical analysis of Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02786498).Phase 2Results postedn = 102NCT02786498
VITALIndependent statistical analysis of A Study of Dog Adoption in Veterans With Posttraumatic Stress Disorder (PTSD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase EARLY_1Results postedn = 19NCT01729026
VITALITY-HFpEFIndependent statistical analysis of Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03547583).Phase 2Results postedn = 789NCT03547583
VitalpsIndependent statistical analysis of Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1/2Results postedn = 23NCT02104505
VIVID-1Independent statistical analysis of A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03926130).Phase 3Results postedn = 1,158NCT03926130
VNeSTIndependent statistical analysis of Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 11NCT01300624
VOR-IISRIndependent statistical analysis of Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02969876).Phase 4Results postedn = 2NCT02969876
VRIndependent statistical analysis of Immersive Virtual Reality in Stroke Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04429945).Phase NAResults postedn = 10NCT04429945
VR-THEIAIndependent statistical analysis of Impact of Virtual Reality on Pre-procedural anxieTy Prior to Heart cathEterIzAtion - VR-THEIA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 180NCT03662607
VRPE ExtensionIndependent statistical analysis of Comparing Virtual Reality Exposure Therapy to Prolonged Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01459705).Phase NAResults postedn = 162NCT01459705
WalkITIndependent statistical analysis of A Walking Intervention Through Text Messaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02053259).Phase NAResults postedn = 96NCT02053259
WILLOW TREEIndependent statistical analysis of The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin: primary endpoint results, effect estimate with…Phase 4Results postedn = 72NCT03869268
WRAPIndependent statistical analysis of Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 63NCT03799341
WU197Independent statistical analysis of Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00656851).Phase NAResults postedn = 24NCT00656851
YeapleIndependent statistical analysis of Clinical Efficacy of a Toothpaste on Hypersensitivity Reduction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01040169).Phase NAResults postedn = 79NCT01040169
YELLOW IIIIndependent statistical analysis of Effect of Evolocumab on Coronary Plaque Characteristics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04710368).Phase 4Results postedn = 137NCT04710368
YOGAMAT-IIIndependent statistical analysis of Optimization and Multi-Site Feasibility of Yoga for Chronic Pain in People in YOGAMAT-II - Phase I: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 20NCT04646148
ZoMARSIndependent statistical analysis of Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 48NCT01348269